The average P/S ratio for UTHR's competitors is 7.09, providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR) exhibits a P/S ratio of 4.05, which is -42.82% above the industry average. Given its robust revenue growth of 17.22%, this premium appears unsustainable.